ProCE Banner Activity

CE / CME

Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Video

In this webinar, explore how to optimize testing and assessment strategies to identify patients most likely to benefit from HER2-targeted antibody–drug conjugate therapy, learn how to develop individualized treatment plans using these therapies, and how to set patients up for success through effective identification and management of treatment-related adverse events.

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: December 01, 2023

Expiration: November 30, 2024

Share

Faculty

Nisha Mohindra

Nisha Mohindra, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine of Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate optimal testing and assessment strategies to identify patients most likely to benefit from HER2-targeted antibody–drug conjugate therapy

  • Develop treatment plans using HER2-directed antibody–drug conjugates considering recent FDA approvals, emerging data, and individualized patient characteristics

  • Prepare strategies for effective identification and management of AEs associated with HER2-targeted therapies considering pharmacologic activity, patient history, and disease- vs drug-related symptoms

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Nisha Mohindra, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine of Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Nisha Mohindra, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Jazz Pharmaceuticals, Regeneron; researcher (paid to institution): AstraZeneca, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 01, 2023, through November 30, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-311-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.